Premium
INTENSIVE IMMUNOCHEMOTHERAPY (R‐CHOEP) VS HIGH‐DOSE IMMUNOCHEMOTHERAPY (R‐MegaCHOEP) IN YOUNG PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA: A 10‐YEAR LONG‐TERM FOLLOW‐UP
Author(s) -
Frontzek F.,
Ziepert M.,
Nickelsen M.,
Altmann B.,
Glaß B.,
Hänel M.,
Trümper L.,
Held G.,
Bentz M.,
Borchmann P.,
Dreyling M.,
Viardot A.,
Metzner B.,
Kroschinsky F.,
Staiger A.M.,
Ott G.,
Rosenwald A.,
Löffler M.,
Lenz G.,
Schmitz N.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.104_2631
Subject(s) - rituximab , medicine , aggressive lymphoma , bcl6 , oncology , autologous stem cell transplantation , lymphoma , clinical endpoint , chemotherapy , immunohistochemistry , gastroenterology , randomized controlled trial , immunology , b cell , antibody , germinal center
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom